MX2020001725A - Anticuerpos de fijacion a nicotina novedosos. - Google Patents
Anticuerpos de fijacion a nicotina novedosos.Info
- Publication number
- MX2020001725A MX2020001725A MX2020001725A MX2020001725A MX2020001725A MX 2020001725 A MX2020001725 A MX 2020001725A MX 2020001725 A MX2020001725 A MX 2020001725A MX 2020001725 A MX2020001725 A MX 2020001725A MX 2020001725 A MX2020001725 A MX 2020001725A
- Authority
- MX
- Mexico
- Prior art keywords
- nicotine
- binding antibodies
- novel nicotine
- novel
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Se describen anticuerpos de fijación a nicotina novedosos y métodos para usarlos para tratar la adicción a la nicotina y/o facilitar el cese del tabaquismo, o para tratar la sobredosis de nicotina o la intoxicación por nicotina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762545696P | 2017-08-15 | 2017-08-15 | |
PCT/US2018/046621 WO2019036419A1 (en) | 2017-08-15 | 2018-08-14 | NEW NICOTINE BINDING ANTIBODIES |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020001725A true MX2020001725A (es) | 2020-08-20 |
Family
ID=63405495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001725A MX2020001725A (es) | 2017-08-15 | 2018-08-14 | Anticuerpos de fijacion a nicotina novedosos. |
Country Status (10)
Country | Link |
---|---|
US (2) | US11440970B2 (es) |
EP (1) | EP3668598A1 (es) |
JP (1) | JP7364555B2 (es) |
KR (1) | KR20200089255A (es) |
CN (1) | CN111432883A (es) |
AU (1) | AU2018317372A1 (es) |
BR (1) | BR112020002994A2 (es) |
CA (1) | CA3072767A1 (es) |
MX (1) | MX2020001725A (es) |
WO (1) | WO2019036419A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021526529A (ja) * | 2018-06-06 | 2021-10-07 | アンティドートゥ・セラピューティクス・インコーポレイテッド | 循環を改善するおよび心血管疾患を治療するための方法 |
KR102530111B1 (ko) * | 2022-03-11 | 2023-05-10 | 앱클론(주) | 코티닌을 표적하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이들의 용도 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5444386A (en) | 1985-03-08 | 1986-09-11 | Baylor College Of Medicine | Anti-nicotine and anti-cotinine antibodies (monoclonal and polyclonal) |
US6232082B1 (en) | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002058635A2 (en) * | 2001-01-26 | 2002-08-01 | The Scripps Research Institute | Nicotine immunogens and antibodies and uses thereof |
US20050089524A1 (en) | 2002-03-01 | 2005-04-28 | Sanderson Sam D. | Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US20060111271A1 (en) | 2004-11-24 | 2006-05-25 | Cerny Erich H | Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements |
US8316104B2 (en) * | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
WO2007064478A2 (en) | 2005-11-28 | 2007-06-07 | Nabi Biopharmaceuticals | Method for making nicotine hapten |
US7547712B2 (en) | 2006-02-27 | 2009-06-16 | Nabi Biopharmaceuticals | Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women |
CN101878228A (zh) * | 2007-11-29 | 2010-11-03 | 赛托斯生物技术公司 | 尼古丁特异性人单克隆抗体 |
EP2065398A1 (en) | 2007-11-29 | 2009-06-03 | Cytos Biotechnology AG | Human monoclonal nicotine specific antibodies |
US8232072B2 (en) | 2008-06-13 | 2012-07-31 | Nabi Biopharmaceuticals | Smoking cessation kit and method |
-
2018
- 2018-08-14 CN CN201880067101.7A patent/CN111432883A/zh active Pending
- 2018-08-14 CA CA3072767A patent/CA3072767A1/en active Pending
- 2018-08-14 BR BR112020002994-7A patent/BR112020002994A2/pt not_active Application Discontinuation
- 2018-08-14 AU AU2018317372A patent/AU2018317372A1/en active Pending
- 2018-08-14 KR KR1020207007504A patent/KR20200089255A/ko not_active Application Discontinuation
- 2018-08-14 MX MX2020001725A patent/MX2020001725A/es unknown
- 2018-08-14 US US16/639,050 patent/US11440970B2/en active Active
- 2018-08-14 JP JP2020509479A patent/JP7364555B2/ja active Active
- 2018-08-14 EP EP18760233.9A patent/EP3668598A1/en active Pending
- 2018-08-14 WO PCT/US2018/046621 patent/WO2019036419A1/en unknown
-
2022
- 2022-08-12 US US17/819,577 patent/US20230089068A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7364555B2 (ja) | 2023-10-18 |
US20200377616A1 (en) | 2020-12-03 |
AU2018317372A1 (en) | 2020-03-05 |
US20230089068A1 (en) | 2023-03-23 |
JP2020531480A (ja) | 2020-11-05 |
CN111432883A (zh) | 2020-07-17 |
CA3072767A1 (en) | 2019-02-21 |
WO2019036419A1 (en) | 2019-02-21 |
BR112020002994A2 (pt) | 2020-08-11 |
KR20200089255A (ko) | 2020-07-24 |
EP3668598A1 (en) | 2020-06-24 |
US11440970B2 (en) | 2022-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202202559B (en) | Kras g12c inhibitors and methods of using the same | |
MX2020002502A (es) | Inhibidores de kras g12c y metodos para utilizarlos. | |
MY196830A (en) | Kras g12c inhibitors and methods of using the same | |
MX2020010836A (es) | Inhibidores de kras g12c y métodos para su uso. | |
MX2021005700A (es) | Inhibidores de kras g12c y metodos de uso de los mismos. | |
MX2020011582A (es) | Inhibidores de kras g12c y metodos para su uso. | |
PH12019502283A1 (en) | Anti-lag3 antibodies | |
MX2018010362A (es) | Metodos y sistemas para evaluar carga mutacional de tumores. | |
MX2016014189A (es) | Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico. | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
PH12020552229A1 (en) | Il-11ra antibodies | |
MX2020003939A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos. | |
ZA201805507B (en) | Dry-process reconstituted tobacco leaf, method and device for producing dry-process reconstituted tobacco leaf | |
PH12019502087A1 (en) | Anti-par2 antibodies and uses thereof | |
NZ727020A (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
NZ762843A (en) | Anti-egfr antibodies and antibody drug conjugates | |
MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
PH12020500576A1 (en) | Method of treating cancers with antagonistic anti-pd-1 antibodies | |
PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
PH12018502137A1 (en) | Anti-complement factor bb antibodies and uses thereof | |
EP3331526A4 (en) | NICOTIN-DEGREEING ENZYMES FOR THE TREATMENT OF NICOTINE DEPENDENCE AND NICOTINE POISONING | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
MX2019009546A (es) | Anticuerpos anti-factor d y uso de los mismos. | |
MX2020001725A (es) | Anticuerpos de fijacion a nicotina novedosos. |